Table 1.
Number and proportion of patients displaying comorbidities of the Medication-Based Disease Burden Index
| Comorbidities | Ranibizumab cohort N (%) | Aflibercept cohort N (%) | P |
|---|---|---|---|
| Month 6 (180 days) | N = 1235 | N = 959 | |
| No disease | 1011 (81.86%) | 809 (84.36%) | 0.12 |
| Alzheimer’s disease and other dementias | 8 (0.65%) | 3 (0.31%) | 0.37 |
| Asthma | 69 (5.59%) | 52 (5.42%) | 0.87 |
| Benign prostatic hypertrophy | 10 (0.81%) | 7 (0.73%) | 0.83 |
| Cerebrovascular disease | 5 (0.40%) | 2 (0.21%) | 0.48 |
| Cirrhosis | 0 (0.00%) | 0 (0.00%) | |
| COPD | 7 (0.57%) | 6 (0.63%) | 0.86 |
| Diabetes mellitus | 66 (5.34%) | 41 (4.28%) | 0.25 |
| Epilepsy | 7 (0.57%) | 6 (0.63%) | 0.86 |
| Hepatitis B | 0 (0.00%) | 0 (0.00%) | |
| Hepatitis C | 0 (0.00%) | 0 (0.00%) | |
| HIV infection | 0 (0.00%) | 0 (0.00%) | |
| Hypertensive heart disease | 3 (0.24%) | 3 (0.31%) | 1.00 |
| Ischemic heart disease | 17 (1.38%) | 9 (0.94%) | 0.35 |
| Malignant neoplasms | 18 (1.46%) | 6 (0.63%) | 0.06 |
| Nephritis/nephrosis | 0 (0.00%) | 0 (0.00%) | |
| Parkinson’s disease | 6 (0.49%) | 2 (0.21%) | 0.48 |
| Peptic ulcer disease | 2 (0.16%) | 0 (0.00%) | 0.51 |
| Rheumatic heart disease | 1 (0.08%) | 3 (0.31%) | 0.32 |
| Skin diseases | 79 (6.40%) | 50 (5.21%) | 0.24 |
| Tuberculosis | 0 (0.00%) | 0 (0.00%) | |
| Month 12 (360 days) | N = 578 | N = 483 | |
| No disease | 475 (82.18%) | 406 (84.06%) | 0.42 |
| Alzheimer’s disease and other dementias | 7 (1.21%) | 2 (0.41%) | 0.19 |
| Asthma | 33 (5.71%) | 25 (5.18%) | 0.70 |
| Benign prostatic hypertrophy | 2 (0.35%) | 2 (0.41%) | 1.00 |
| Cerebrovascular disease | 2 (0.35%) | 1 (0.21%) | 1.00 |
| Cirrhosis | 0 (0.00%) | 0 (0.00%) | |
| COPD | 5 (0.87%) | 3 (0.62%) | 0.73 |
| Diabetes mellitus | 27 (4.67%) | 19 (3.93%) | 0.56 |
| Epilepsy | 3 (0.52%) | 3 (0.62%) | 1.00 |
| Hepatitis B | 0 (0.00%) | 0 (0.00%) | |
| Hepatitis C | 0 (0.00%) | 0 (0.00%) | |
| HIV infection | 0 (0.00%) | 0 (0.00%) | |
| Hypertensive heart disease | 2 (0.35%) | 3 (0.62%) | 0.66 |
| Ischemic heart disease | 11 (1.90%) | 5 (1.04%) | 0.25 |
| Malignant neoplasms | 7 (1.21%) | 3 (0.62%) | 0.36 |
| Nephritis/nephrosis | 0 (0.00%) | 0 (0.00%) | |
| Parkinson’s disease | 1 (0.17%) | 1 (0.21%) | 1.00 |
| Peptic ulcer disease | 0 (0.00%) | 0 (0.00%) | |
| Rheumatic heart disease | 1 (0.17%) | 2 (0.41%) | 0.59 |
| Skin diseases | 35 (6.06%) | 28 (5.80%) | 0.86 |
| Tuberculosis | 0 (0.00%) | 0 (0.00%) |
Differences in proportion tests were used to compare the proportion of patients displaying the different comorbidities for each treatment cohort. Analyses were conducted with the final month 6 and month 12 study cohorts